The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
24/7 Wall St. on MSN1h
3 Top Dividend Stocks to Buy in February
Dividend stocks are increasingly appealing for investors in 2025 due to their potential for steady income and resilience in volatile markets. As the economic landscape evolves, characterized by rising ...